Jacobs Levy Equity Management Inc. Has $2.78 Million Position in Inogen, Inc. (NASDAQ:INGN)

Jacobs Levy Equity Management Inc. raised its stake in Inogen, Inc. (NASDAQ:INGN) by 4.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 303,522 shares of the medical technology company’s stock after buying an additional 12,654 shares during the period. Jacobs Levy Equity Management Inc. owned about 1.27% of Inogen worth $2,783,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Price T Rowe Associates Inc. MD raised its holdings in Inogen by 5.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 26,710 shares of the medical technology company’s stock worth $245,000 after purchasing an additional 1,318 shares during the last quarter. Invesco Ltd. raised its stake in Inogen by 2.0% during the fourth quarter. Invesco Ltd. now owns 78,142 shares of the medical technology company’s stock worth $717,000 after buying an additional 1,545 shares during the last quarter. Wells Fargo & Company MN lifted its holdings in Inogen by 27.8% in the fourth quarter. Wells Fargo & Company MN now owns 13,917 shares of the medical technology company’s stock valued at $128,000 after buying an additional 3,031 shares during the period. Bank of America Corp DE boosted its position in Inogen by 2.7% during the fourth quarter. Bank of America Corp DE now owns 127,326 shares of the medical technology company’s stock valued at $1,168,000 after acquiring an additional 3,304 shares during the last quarter. Finally, AlphaQuest LLC acquired a new stake in Inogen during the 4th quarter worth about $43,000. Institutional investors and hedge funds own 89.94% of the company’s stock.

Inogen Trading Down 2.2%

INGN opened at $5.75 on Friday. The company has a fifty day moving average price of $7.02 and a two-hundred day moving average price of $8.82. Inogen, Inc. has a 1-year low of $5.70 and a 1-year high of $13.33. The company has a market cap of $154.60 million, a P/E ratio of -2.56 and a beta of 1.63.

Inogen (NASDAQ:INGN) last issued its earnings results on Wednesday, May 7th. The medical technology company reported ($0.25) EPS for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.27. The business had revenue of $82.28 million during the quarter, compared to analyst estimates of $79.57 million. Inogen had a negative return on equity of 27.38% and a negative net margin of 15.89%. On average, research analysts forecast that Inogen, Inc. will post -1.73 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently commented on INGN. Needham & Company LLC restated a “hold” rating on shares of Inogen in a research report on Wednesday, April 9th. StockNews.com lowered Inogen from a “buy” rating to a “hold” rating in a research note on Wednesday, February 26th. Finally, Stifel Nicolaus reduced their price objective on shares of Inogen from $10.00 to $7.00 and set a “hold” rating for the company in a research report on Thursday, May 8th.

Inogen Company Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.